 CAMBRIDGE, Mass.--BUSINESS WIRE--- VBIV--VBI Vaccines Inc. Nasdaq: VBIV VBI, a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the European Medicines Agency EMA has accepted the filing of the Marketing Authorization Application MAA for the Companys 3-antigen prophylactic hepatitis B vaccine candidate for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults. The a 